pWRG/HTN-M(co)/pWRG/PUUV-M(s2)

Drug Profile

pWRG/HTN-M(co)/pWRG/PUUV-M(s2)

Alternative Names: Hantaan virus/puumala virus DNA vaccine; Hantaan/puumala virus DNA vaccine; Hantaan/puumala virus vaccine; HTNV/PUU DNA vaccine; HTNV/PUUV DNA vaccine; Puumala/hantaan virus DNA vaccine; pWRG/HTN-M(co)/pWRG/PUU-M(s2); pWRG/HTN-M(x)/pWRG/PUU-M(s2); pWRG/HTN-M(x)/pWRG/PUUV-M(s2)

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Ichor Medical Systems; United States Army Medical Research and Materiel Command
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Viral haemorrhagic fevers

Most Recent Events

  • 26 Dec 2016 Phase-II development is ongoing in USA (NCT02116205)
  • 01 Aug 2016 United States Army Medical Research and Materiel Command initiates a phase I trial in Viral haemorrhagic fevers (Prevention) in USA (IM) (NCT02776761)
  • 17 May 2016 United States Army Medical Research and Materiel Command plans a phase I trial in Viral haemorrhagic fevers (Prevention) in USA (IM) (NCT02776761)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top